SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- cardiovascular -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (69)11/17/2003 7:06:26 PM
From: Miljenko Zuanic  Respond to of 214
 
Tuck,

It appears that Enox is more effective than Dobutamine (at least as i.v. formulation). Also, it may be that their PIII program may generate approval base. However, what are current IP status and how they will be protected from generic? They will (may??) have 7 years exclusivity, which is sufficient for now.

Miljenko